What is Mallinckrodt plc (MNKKQ)?

Mallinckrodt plc (MNKKQ) is a stock in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry. View full analysis on Stocks360.

What is the current price of MNKKQ?

The current price of MNKKQ is $0.02. Prices are updated in real time on Stocks360.

What is MNKKQ's price-to-earnings (PE) ratio?

MNKKQ's trailing twelve-month PE ratio is -0.00, based on current price and earnings per share data available on Stocks360.

Mallinckrodt plc (MNKKQ)

Stock analysis · OTC · Healthcare · Drug Manufacturers - Specialty & Generic

$0.02

Market Cap

N/A

PE (TTM)

-0.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

2.72

Day Range

$0.02 – $0.02

52-wk Range

$0.00 – $0.36

Avg Volume

N/A

Volume

290.54K

Mallinckrodt plc (MNKKQ) is a publicly traded company in the Healthcare sector. Latest price: $0.02. Trailing PE -0.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

Earnings

Most Recent

Mar 10, 2021

EPS $0.73 vs est. $1.44

Missed by $0.71

Proprietary Signals

Signal snapshot temporarily unavailable.

About Mallinckrodt plc

Headquartered in Dublin, Ireland, Mallinckrodt plc is engaged in the global development, manufacturing, commercialization, and distribution of specialized pharmaceutical products and therapeutic solutions. The company operates through two primary divisions: Specialty Brands and Specialty Generics. Its Specialty Brands division focuses on proprietary pharmaceutical products addressing autoimmune and rare diseases across multiple therapeutic areas, including neurology, rheumatology, nephrology, ophthalmology, pulmonology, and oncology. This segment also encompasses immunotherapies, neonatal respiratory critical care treatments, analgesics, cultured skin substitutes, and gastrointestinal medications. Among its flagship products are Acthar Gel, a repository corticotropin injection prescribed for various conditions such as rheumatoid arthritis, infantile spasms, systemic lupus erythematosus, multiple sclerosis, systemic dermatomyositis, symptomatic sarcoidosis, and severe acute and chronic allergic and inflammatory diseases. Other notable offerings include INOmax, a vasodilator designed to improve oxygenation and reduce the necessity for extracorporeal membrane oxygenation; the Therako…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.00×
P/S (TTM)	0.00×
P/B	0.00×
PEG	0.00×
P/FCF (TTM)	0.00×
EV / EBITDA	-296.21×
EV / Sales	1.04×
Earnings Yield	-58611.11%
Free Cash Flow Yield	0.00%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.57B
Revenue (TTM)	$1.51B
Net Income (TTM)	$0.00
Free Cash Flow (TTM)	$381.93M
Net Debt	$1.57B
Working Capital	$1.55B
Gross Margin	44.78%
Operating Margin	-54.24%
Net Margin	-30.72%
Return on Equity	-20.79%
Return on Invested Capital	-16.45%